MindMed Plans to Use the Phase 1 Study to Experiment with Dosing Methods to Better Understand How Humans React to Ayahuasca’s Active Ingredient, DMT The Phase 1 Clinical Trials Will Put MindMed in a Position to Potentially Progress to Phase 2A Proof of Concept Trials Down the Road Psychedelics pharma leader MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: BGHM) announced Thursday the company is gearing up to begin a new Phase 1 clinical trial in conjunction with the Swiss-based Liechti Lab at the University Hospital Basel. The study, expected to begin in Q4 of 2020, will focus on the psychedelic substance DMT and its effect on humans. MindMed, which is backed by Shark Tank billionaire Kevin O’Leary and Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) founder Bruce Linton will provide the startup funding for the Phase 1 clinical trial intended to test various intravenous DMT dosing procedures. N,N-Dimethyltryptamine, aka DMT, is a well-known and naturally-occurring psychedelic substance and is the main ingredient in the psychoactive brew Ayahuasca. Compared to similar psychedelics like LSD and Psilocybin (Magic Mushrooms), DMT has a rapid onset and offset action with its hallucinogenic effects lasting on average for around 30 minutes. Traditionally, Ayahuasca has used …
